OPDP letter criticizes drug company for failing to disclose risk info online
The FDA Office of Prescription Drug Promotion (OPDP) on Monday unveiled a new untitled letter sent last week to Michigan-based Rockwell Medical
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
